Paper proposes a model to integrate diverse drug features for accurate similarity measures.
problem Challenges in integrating heterogeneous, noisy, nonlinear-related drug features.
method Attentive Multi-view Graph Auto-Encoders with flexible design for semi-supervised and unsupervised settings.
result Significant predictive accuracy improvement and better interpretability.
Improves drug properties using a novel LLM and reinforcement learning.
problem Optimizing drug properties while retaining chemical stability.
method Structured Policy Optimization (SPO) for fine-tuning a large language model.
result Enhanced drug properties across multiple target objectives.
Paper proposes a framework to predict therapeutic properties of compounds.
problem Predict therapeutic properties of compounds with heterogeneous data.
method Domain-adversarial multi-task framework using adversarial learning.
result Framework improves performance over competitive baselines.
CoDrug uses KDE to create valid prediction sets for drug molecules under covariate shift.
problem Creating reliable uncertainty estimates for drug properties from computational models.
method CoDrug employs an energy-based model and KDE to assess and rectify distribution shift.
result CoDrug reduces the coverage gap by over 35% compared to non-adjusted conformal prediction sets.
Quantum machine learning boosts drug discovery efficiency.
problem Enhancing drug discovery through quantum computing.
method Quantum neural networks on gate-based quantum computers.
result Significant advancements in molecular property prediction and generation.
Study links different drug property prediction methods and datasets.
problem Unclear which method is best for drug property prediction.
method Empirical study linking multiple datasets and methods.
result Best method depends on dataset, classical methods often outperform deep learning.
A new method learns graph-level features for drug properties predication.
problem Predicting drug efficacy and toxicity from molecular graphs.
method Introducing a dummy super node connected to all nodes and modifying graph operations to learn graph-level features.
result The method improves molecular properties predication performance on MoleculeNet.
Generative model creates drug-like molecules with multiple properties.
problem Designing molecules with multiple desired properties.
method Conditional Variational Autoencoder (VAE) in latent space control.
result Can generate drug-like molecules with five target properties.
A new drug embedding method using hierarchical drug relations and chemical structures.
problem Learning accurate drug representations from chemical structures and hierarchies.
method Semi-supervised drug embedding using VAE in hyperbolic space.
result The method accurately places drugs in a hierarchy and predicts side-effects.
Algorithm generates new drug molecules from prototypes, showing diversity and validity.
problem Designing new drugs from existing prototypes is expensive and time-consuming.
method Conditional Diversity Networks (CDN) for unsupervised generation of drug molecules.
result Generated molecules are valid and significantly different from prototypes, including FDA-approved drugs.
DESMILES uses deep learning to improve drug discovery by optimizing molecule properties.
problem Improving the efficiency and accuracy of drug discovery through better molecular design.
method DESMILES is a deep neural network model that optimizes molecular properties for drug discovery.
result DESMILES achieved a 77% lower failure rate in modifying molecules to inhibit the dopamine receptor D2 compared to state-of-the-art models.
NLP techniques improve drug discovery by analyzing chemical and protein text.
problem Improving drug discovery through better analysis of chemical and protein text.
method Natural language processing techniques applied to biochemical entities.
result Enhanced prediction of molecular properties and design of novel molecules.
Visualizes deep generative models for drug design.
problem Limited visualization tools for deep generative models in drug discovery.
method Proposes a visualization framework for deep graph generative models.
result Interactive visualization and molecular optimization tools.
New dataset abla2DFT for drug-like molecules benchmarks neural network potentials.
problem Lack of large, diverse datasets for training neural network potentials in quantum chemistry.
method Developed a new dataset abla2DFT containing energies, forces, and molecular properties for drug-like molecules. result First dataset with relaxation trajectories for drug-like molecules.
The study compares Euclidean and cosine distances in medical drug prescription prediction.
problem Comparing Euclidean and cosine distances in medical drug prescription prediction.
method Established geometric properties and compared distances in real-world medical data.
result Different distances lead to different optimizing nonlinear kernel embedding frameworks.
Deep learning predicts synergistic drug combinations from multi-omics data.
problem Predicting effective drug combinations to overcome cancer drug resistance.
method AuDNNsynergy model integrating gene expression, copy number, genetic mutation data and drug properties.
result AuDNNsynergy model outperforms state-of-the-art approaches.
Mol-CycleGAN generates optimized molecules with similar structure.
problem Designing molecules with desired properties is challenging.
method CycleGAN-based model that generates optimized compounds with high structural similarity.
result Significantly outperforms previous results in optimizing penalized logP of drug-like molecules.
POEM predicts drug properties without tuning, outperforming other methods.
problem Predicting drug properties from molecular structures efficiently.
method POEM combines multiple molecular representations without hyperparameter tuning.
result POEM outperforms industry-standard methods across 17 tasks.
AI helps in drug discovery with understandable explanations.
problem Understanding the complex models behind AI-generated drugs.
method Explainable AI methods to interpret deep learning models.
result Improved interpretability of AI-generated drug properties.
Paper proposes a method to design molecules with specific properties.
problem Designing molecules with desired chemical and biological properties.
method Energy-based model in latent space, SGDS algorithm for gradual distribution shifting.
result Method achieves strong performances on various molecule design tasks.
Generative model tailors anticancer drugs based on transcriptomic data.
problem Designing effective anticancer drugs considering genetic profiles.
method RL framework using pretrained VAEs to generate compounds conditioned on transcriptomic data.
result Generative model produces molecules with high predicted inhibitory effects.
Generative model learns to create molecules with multiple properties using interpretable substructures.
problem Creating molecules with multiple chemical properties is challenging.
method Compose molecules from substructures identified as responsible for each property, using graph generative models.
result Significant improvements in accuracy, diversity, and novelty of generated compounds over state-of-the-art baselines.
DOCKSTRING simplifies docking simulations for better drug design benchmarks.
problem Lack of meaningful benchmarks for ligand design.
method Open-source Python package for docking scores, extensive dataset, and pharmaceutically-relevant tasks.
result Docking scores are more appropriate benchmarks than simple physicochemical properties.
In de novo drug design, computational strategies are used to generate novel molecules with good affinity to the desired biological target. In this work, we show that recurrent neural networks can be trained as generative models for molecular structures, similar to statistical language models in natural language process…
BOAT optimizes multiple antibody properties efficiently.
problem Balancing multiple drug-like properties in antibody design.
method Bayesian optimization framework coupling surrogate modeling and genetic algorithm.
result Competitive performance with state-of-the-art multi-objective protein optimization methods.
MolecularRNN generates realistic molecules with desired properties.
problem Designing new molecules with specific properties.
method Graph recurrent generative model with likelihood pretraining and policy gradient tuning.
result Significant distribution shift to desired ranges for lipophilicity, drug-likeness, and melting point.
Meta-learning improves GNN initializations for low-resource drug discovery.
problem Limited labeled data hinders deep learning in drug discovery.
method Model-Agnostic Meta-Learning (MAML) and its variants for graph neural networks initializations.
result Meta-initializations outperform multi-task pre-training baselines on 16 out of 20 tasks and all out-of-distribution tasks.
Method integrates logical rules into neural multi-hop reasoning for drug repurposing.
problem Capturing long-range dependencies in biomedical data.
method Combines logical rules with neural multi-hop reasoning using reinforcement learning.
result Our method outperforms baseline methods in drug repurposing tasks.
PanRep learns universal node embeddings for heterogeneous graphs.
problem Learning universal node embeddings for heterogeneous graphs.
method Graph Neural Network (GNN) model with four decoders capturing different properties.
result PanRep outperforms unsupervised and supervised methods in node classification and link prediction.
HiGraphDTI learns drug and target representations from molecular graphs to predict DTIs.
problem Inaccurate drug-target interaction prediction due to insufficient chemical information extraction.
method Hierarchical graph representation learning to extract chemical information from atoms, motifs, and molecules.
result HiGraphDTI outperforms state-of-the-art methods in DTI prediction and interaction interpretation.
Recent advances in machine learning have made significant contributions to drug discovery. Deep neural networks in particular have been demonstrated to provide significant boosts in predictive power when inferring the properties and activities of small-molecule compounds. However, the applicability of these techniques …
DECAF optimizes molecular graphs for ensemble properties, improving drug design accuracy.
problem Designing molecules with ensemble properties rather than single conformations.
method DECAF uses Boltzmann-expected design with decoupled annealing flows to optimize molecular graphs.
result DECAF optimizes molecular graphs to shift ensemble properties towards targets, improving accuracy over single-conformer methods.
Benchmark proposes to assess molecule docking efficiency.
problem Lack of realistic benchmarks for measuring progress in drug design.
method Proposes a docking-based benchmark using SMINA software.
result Graph-based generative models fail to generate high-scoring molecules.
New methods predict drug interactions using drug co-medication patterns and graph matching.
problem Predicting adverse drug reactions from drug combinations.
method Developed novel kernels over drug combinations using support vector machines and graph matching to measure similarities.
result Achieved an AUC of 0.912 on a real-world dataset.
AI models struggle to generate diverse natural chemical structures.
problem Generating diverse chemical structures for drug discovery.
method Quantified internal chemical diversity; challenge with two models.
result AI models fail to reproduce natural chemical diversity.
Paper proposes a method to efficiently generate molecules with desired properties.
problem Challenging to explore a large chemical space efficiently.
method Semi-supervised variational autoencoder trained on existing molecules with partial annotation.
result Improves property prediction and efficiently generates novel molecules.
Paper tackles multi-task learning for molecular property prediction with limited data.
problem Limited labeled data for each molecular property task in drug discovery.
method Proposes SGNN-EBM method to utilize relation graph between tasks and improve multi-task learning performance.
result Empirical results show the effectiveness of SGNN-EBM.
A new model designs molecular latent vectors for drug discovery.
problem Designing effective molecular descriptors from molecular structures.
method Proposes a denoising diffusion probabilistic model (DDPM) for variational autoencoding molecular graphs.
result Demonstrates superior prediction performance and robustness compared to existing approaches.
Enhances drug discovery models by understanding human language.
problem Low predictive quality of activity prediction models in drug discovery.
method Proposes a novel architecture with separate chemical and natural language input modules and a contrastive pre-training objective.
result Improves predictive performance on few-shot and zero-shot learning benchmarks.
A new RL framework optimizes drug-like molecules synthetically.
problem Optimizing drug-like molecules for specific criteria.
method Deep Reinforcement Learning framework for chemical space optimization.
result Outperforms existing methods in pharmacological optimization.
New method predicts drug interactions from drug images.
problem Predicting drug interactions from molecular structures.
method Siamese neural network using drug structure images.
result First work predicting DDIs from drug images.
New method predicts cancer drug rankings based on genomic data.
problem Selecting the right drugs for cancer patients.
method pLETORg method that predicts drug ranking structures using latent vectors.
result pLETORg significantly outperforms state-of-the-art methods in prioritizing new sensitive drugs.
Graph-augmented CNN predicts drug interactions with high accuracy.
problem Predicting drug-drug interactions (DDIs) with high accuracy.
method Combining graph CNN with an attentive pooling network to extract structural relations between drug pairs.
result Desirable performance with ROC 0.988, F1-score 0.956, and AUPR 0.986.
Models predict drug interactions with high accuracy.
problem Detecting drug-drug interactions to prevent medical injuries.
method Artificial neural networks and graph similarity measures.
result Models achieve high accuracy in predicting drug interactions.
Deep Rule Forests identifies drug-drug and drug-disease interactions causing AKI.
problem Identifying drug-drug and drug-disease interactions leading to AKI.
method Deep Rule Forests (DRF) algorithm discovering rules from multilayer tree models.
result DRF model outperforms other algorithms in prediction accuracy and interpretability.
SMILES Transformer learns molecular fingerprints for drug discovery.
problem Poor performance of rule-based molecular fingerprints in shallow prediction models or small datasets.
method Unsupervised pre-training of a sequence-to-sequence language model on a corpus of SMILES.
result SMILES Transformer outperformed existing methods in small-data settings.
CardiGraphormer uses SSL and GNNs to improve drug discovery.
problem Challenges in drug discovery due to combinatorial chemical space and limited approved drugs.
method Combines self-supervised learning, Graph Neural Networks, and Cardinality Preserving Attention.
result Enhanced predictive performance and interpretability in drug discovery.
NetBiTE predicts drug sensitivity and identifies biomarkers in cancer.
problem Predicting drug sensitivity and identifying biomarkers in cancer.
method NetBiTE combines prior knowledge and gene expression data using a biased tree ensemble approach.
result NetBiTE outperforms RF in predicting IC50 drug sensitivity for drugs targeting membrane receptor pathways.